Reaction

Cystoid Macular Oedema reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,837 reports · 45 co-occurring drugs

As of the last recalculation, Cystoid Macular Oedema appears in 1,837 FAERS reports alongside 45 co-occurring drug terms. The strongest observed disproportionality signal is RANIBIZUMAB (PRR 82.5).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ranibizumab	175	82.5	83.0
Prednisolone Acetate	46	51.6	51.9
Paclitaxel (Aibumin-Bound)	203	31.3	31.4
Paclitaxel	227	29.5	29.6
Faricimab	17	24.0	24.0
Timolol	23	21.8	21.9
Encorafenib	16	18.5	18.5
Brimonidine Tartrate	27	17.4	17.4
Dorzolamide Hydrochloride And Timolol Maleate	12	17.3	17.3
Aflibercept	46	17.1	17.1
Cefuroxime	17	17.0	17.0
Insulin Glulisine	15	16.8	16.9
Adalimumab-Fkjp	66	16.7	16.7
Adalimumab-Aaty	66	16.4	16.4
Bimatoprost	38	15.2	15.3
Anastrozole Tablets	28	15.0	15.0
Adalimumab-Adaz	67	14.9	14.9
Bevacizumab	150	14.9	14.9
Brinzolamide	11	14.4	14.4
Latanoprost	57	13.2	13.2
Moxifloxacin Hydrochloride	23	13.0	13.0
Triamcinolone Acetonide	34	12.7	12.7
Cefazolin	10	12.5	12.5
Cefazolin Sodium	13	12.3	12.3
Travoprost	9	11.8	11.9
Triamcinolone Acetonide Ointment Usp, 0.05%	23	11.3	11.3
Ganciclovir	10	11.1	11.1
Fingolimod Hcl	81	11.1	11.1
Ganciclovir Sodium	10	10.8	10.8
Siponimod	7	8.9	8.9
Anastrozole	28	8.8	8.8
Gemcitabine	30	8.8	8.8
Hydroxychloroquine	53	8.3	8.3
Niacin	8	7.8	7.8
Vemurafenib	8	7.6	7.6
Gemcitabine Hydrochloride	31	6.7	6.7
Docetaxel Anhydrous	38	6.5	6.5
Docetaxel	38	6.5	6.5
Letrozole Tablets	27	6.4	6.4
Trastuzumab	38	6.4	6.4
Tramadol Hydrochloride	21	6.4	6.4
Ibrutinib	38	5.4	5.4
Abemaciclib	9	5.1	5.1
Ipilimumab	12	3.2	3.2
Lifitegrast	3	2.1	2.1

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.